Combination treatment of WT B-ALL-bearing mice with doxorubicin and PD-L1 antibody-blocking therapy reduced leukemia burden in a subset of mice (Fig. 5b) and increased their survival (Fig. 5c). This evidence concerns the gene CD274 and acute lymphoblastic leukemia.